Highly selective cyclooxygenase-1 inhibitors P6 and mofezolac counteract inflammatory state both in vitro and in vivo models of neuroinflammation

Frontiers in Neurology

Volumn 8, Issue JUN, 2017, Pages

  Calvello, Rosa ^a   Lofrumento, Dario Domenico ^b   Perrone, Maria Grazia ^a   Cianciulli, Antonia ^a   Salvatore, Rosaria ^a   Vitale, Paola ^a   De Nuccio, Francesco ^b   Giannotti, Laura ^b   Nicolardi, Giuseppe ^b   Panaro, Maria Antonietta ^a   Scilimati, Antonio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF SALENTO   (Italy)

Author keywords

Cyclooxygenase 1; Cyclooxygenase 1 inhibitors; In vitro and in vivo experiments; Lipopolysaccharide treated BV2 microglial cells; Neuroinflammation; P6 and mofezolac

Indexed keywords

CALCIUM BINDING PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IONIZED CALCIUM BINDING ADAPTER MOLECULE 1; MOFEZOLAC; P 6; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 85020754401     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2017.00251     Document Type: Article

References (34)

1. Filiou MD, Arefin AS, Moscato P, Graeber MB. Neuroinflammation differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared. Neurogenetics (2014) 15:201-12. doi:10.1007/s10048-014-0409-x
2. Xu L, He D, Bai Y. Microglia-mediated inflammation and neurodegenerative disease. Mol Neurobiol (2016) 53:6709-15. doi:10.1007/s12035-015-9593-4
3. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 74:691-705. doi:10.1016/j.neuron.2012.03.026
4. Hughes V. Microglia: the constant gardeners. Nature (2012) 485:570-2. doi:10.1038/485570a
5. Gemma C, Bachstetter AD. The role of microglia in adult hippocampal neurogenesis. Front Cell Neurosci (2013) 7:229. doi:10.3389/fncel.2013.00229
6. Nakanishi H, Hayashi Y, Wu Z. The role of microglial mtDNA damage in age-dependent prolonged LPS-induced sickness behavior. Neuron Glia Biol (2011) 7:17-23. doi:10.1017/S1740925X1100010X
7. Choi DK, Koppula S, Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules (2011) 16:1021-43. doi:10.3390/molecules16021021
8. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell (2010) 140:918-34. doi:10.1016/j.cell.2010.02.016
9. RansohoffRM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol (2009) 27:119-45. doi:10.1146/annurev.immunol.021908.132528
10. Cacciatore I, Marinelli L, Fornasari E, Cerasa LS, Eusepi P, Türkez H, et al. Novel NSAID-derived drugs for the potential treatment of Alzheimer's disease. Int J Mol Sci (2016) 17:E1035. doi:10.3390/ijms17071035
11. Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and-2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci (2009) 30:174-81. doi:10.1016/j.tips.2009.01.002
12. Vitale P, Scilimati A, Perrone MG. Update on SAR studies toward new COX-1 selective inhibitors. Curr Med Chem (2015) 22:4278-92. doi:10.2174/0929867322666151029104717
13. Vitale P, Panella A, Scilimati A, Perrone MG. COX-1 inhibitors: beyond structure toward therapy. Med Res Rev (2016) 36:641-71. doi:10.1002/med.21389
14. Calvello R, Panaro MA, Carbone ML, Cianciulli A, Perrone MG, Vitale P, et al. Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells. Pharmacol Res (2012) 65:137-48. doi:10.1016/j.phrs.2011.09.009
15. Di Nunno L, Vitale P, Scilimati A, Tacconelli S, Patrignani P. Novel synthesis of 3, 4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem (2004) 47:4881-90. doi:10.1021/jm040782x
16. Micetich RG. 3, 4-Diarylisoxazol-5-Acetic Acid Compounds, Process for Preparing the Same, and Pharmaceuticals Containing the Same. European patent EP 0026928 A1 (1981)
17. Bi W, Zhu L, Jing X, Zeng Z, Liang Y, Xu A, et al. Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway. Mol Med Rep (2014) 10:1793-9. doi:10.3892/mmr.2014.2480
18. Haw RT, Tong CK, Yew A, Lee HC, Phillips JB, Vidyadaran S. A three-dimensional collagen construct to model lipopolysaccharide-induced activation of BV2 microglia. J Neuroinflammation (2014) 11:134-44. doi:10.1186/1742-2094-11-134
19. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat (2002) 68:165-75. doi:10.1016/S0090-6980(02)00029-1
20. Aïd S, Bosetti F. Targeting cyclooxygenases-1 and-2 in neuroinflammation: therapeutic implications. Biochimie (2011) 93:46-51. doi:10.1016/j.biochi.2010.09.009
21. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res (1999) 830:226-36. doi:10.1016/S0006-8993(99)01389-X
22. Matousek SB, Hein AM, Shaftel SS, Olschowka JA, Kyrkanides S, O'Banion MK. Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem (2010) 114:247-58. doi:10.1111/j.1471-4159.2010.06759.x
23. Aïd S, Silva AC, Candelario-Jalil E, Choi SH, Rosenberg GA, Bosetti FJ. Cyclooxygenase-1 and-2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab (2010) 30:370-80. doi:10.1038/jcbfm.2009.223
24. Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, et al. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice. Prostaglandins Other Lipid Mediat (1998) 56:245-54. doi:10.1016/S0090-6980(98)00054-9
25. Abdelazeem AH, El-Saadi MT, SafiEl-Din AG, Omar HA, El-Moghazy SM. Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile. Bioorg Med Chem (2017) 25:665-76. doi:10.1016/j.bmc.2016.11.037
26. Milatovic D, Zaja-Milatovic S, Montine KS, Horner PJ, Montine TJ. Pharmacologic suppression of neuronal oxidative damage and dendritic degeneration following direct activation of glial innate immunity in mouse cerebrum. J Neurochem (2003) 87:1518-26. doi:10.1046/j.1471-4159.2003.02120.x
27. Barrientos RM, Kitt MM, Watkins LR, Maier SF. Neuroinflammation in the normal aging hippocampus. Neuroscience (2015) 309:84-99. doi:10.1016/j.neuroscience.2015.03.007
28. Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, et al. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomod (2011) 18:79-88. doi:10.1159/000320027
29. Lim A, Krajina K, Marsland AL. Peripheral inflammation and cognitive aging. Mod Trends Pharmacopsychiatry (2013) 28:175-87. doi:10.1159/000346362
30. Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging (Albany NY) (2009) 1:234-44. doi:10.18632/aging.100021
31. Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J (2008) 22:1491-501. doi:10.1096/fj.07-9411com
32. Shukuri M, Mawatari A, Ohno M, Suzuki M, Doi H, Watanabe Y, et al. Detection of cyclooxygenase-1 in activated microglia during amyloid plaque progression: PET studies in Alzheimer's disease model mice. J Nucl Med (2016) 57:291-6. doi:10.2967/jnumed.115.166116
33. Aïd S, Bosetti F. Targeting cyclooxygenases-1 and-2 in neuroinflammation: Therapeutic implications. Biochimie (2011) 93:46-51. doi:10.1016/j.biochi.2010.09.009
34. Janova H, Böttcher C, Holtman IR, Regen T, van Rossum D, Götz A, et al. CD14 is a key organizer of microglial responses to CNS infection and injury. Glia (2016) 64:635-49. doi:10.1002/glia.22955